Join the Acute Myeloid Leukemia group to help and get support from people like you.
Acute Myeloid Leukemia News
Related terms: Acute Granulocytic Leukemia, Acute Myelogenous Leukemia, ANLL, Cancer, Acute Granulocytic Leukemia, Cancer, Acute Myelogenous Leukemia, Cancer, Acute Myeloid Leukemia, Leukemia, Acute Granulocytic, Leukemia, Acute Myelogenous, Leukemia, Acute Myeloid, AML
Leukemia Stem Cell-Based Method Aids Relapse Prediction in Acute Myeloid Leukemia
FRIDAY, Aug. 29, 2025 – An assay that uses leukemia stem cells (LSCs) to assess measurable residual disease (MRD) outperforms traditional methods in patients with acute myeloid leukemia (AML),...
Rezlidhia May Also Fight a Deadly Bone Marrow Disorder
TUESDAY, Aug. 5, 2025 — A recently approved leukemia pill also might help some patients diagnosed with a deadly bone marrow disorder, a new pilot study says. About 3 in 5 patients with m...
Molecular Monitoring Improves Survival in Some Patients With Newly Diagnosed Leukemia
WEDNESDAY, May 14, 2025 – Molecular monitoring of measurable residual disease (MRD), coupled with guided treatment, contributes to improved survival for patients with newly diagnosed acute myeloid...
Disparities Identified in Leukemia Incidence, Mortality in Florida
TUESDAY, March 25, 2025 – There are racial and geographic disparities in the incidence of and mortality from adult leukemia in Florida, where the incidence of leukemia is the highest in the United...
FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ – Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and...
Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
THURSDAY, Oct. 24, 2024 – Protracted low-dose exposure to ionizing radiation among radiation-monitored workers is associated with mortality due to some hematologic malignancies, according to a study...
Overall Survival Improving for Umbilical Cord Blood Transplant
MONDAY, Oct. 7, 2024 – For umbilical cord blood transplant (UCBT), overall survival has improved over time, according to a study published in the October issue of Transplantation and Cellular...
FDA Approves Vanflyta (quizartinib) for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
TOKYO & BASKING RIDGE, N.J. July 20, 2023 --(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that Vanflyta (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in...
FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Rezlidhia is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML...
Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data...
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
DUBLIN, March 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and c...
FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets,...
Agios Announces FDA Approval of Tibsovo as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) – Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food...
FDA Medwatch Alert: FDA Warns That Symptoms of a Serious Condition Affecting the Blood Cells Are Not Being Recognized with the Leukemia Medicine Idhifa (enasidenib)
The U.S. Food and Drug Administration (FDA) is warning that signs and symptoms of a life-threatening side effect called differentiation syndrome are not being recognized in patients receiving the...
FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation
November 28, 2018 – The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia...